Texas Tech University Health Sciences Center at Lubbock Ophthalmology

Topics

• Retinal Diseases and Treatments 108
• Corneal surgery and disorders 34
• Glaucoma and retinal disorders 25
• Retinal and Macular Surgery 20
• Ophthalmology and Visual Impairment Studies 18
• Ocular Infections and Treatments 17
• Corneal Surgery and Treatments 12
• Intraocular Surgery and Lenses 12
• Retinal Development and Disorders 10
• Ocular Diseases and Behçet’s Syndrome 7
• Ocular Surface and Contact Lens 7
• Retinal and Optic Conditions 6

Most cited

1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

   Lancet (London, England) · 2022 · 670 citations · Arshad Khanani

2. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.

   Ophthalmology · 2024 · 192 citations · Arshad Khanani

3. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.

   Lancet (London, England) · 2023 · 299 citations · Arshad Khanani

4. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.

   Eye (London, England) · 2023 · 157 citations · Arshad Khanani

5. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study.

   Lancet (London, England) · 2024 · 110 citations · Arshad Khanani

6. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.

   Ophthalmology · 2024 · 70 citations ·